An experimental antibody treatment reduced viral load in some COVID-19 patients. That may also be a positive sign for vaccines

Promising new clinical data for an experimental COVID-19 treatment hints at a secondary but possibly more important takeaway for investors: if this neutralizing antibody treatment works in coronavirus patients, so will the vaccines that are in development.

Regeneron Pharmaceuticals Inc. REGN, +1.49% on Tuesday shared preliminary data from a Phase 1/2/3 clinical trial for REGN-COV2, finding that the investigational therapy reduced viral load and made symptoms go away sooner in some non-hospitalized patients with mild or moderate cases of COVID-19. It was most effective in patients with higher viral loads...